Akebia Therapeutics, Inc. (AKBA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Akebia Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Akebia Therapeutics, Inc. (AKBA) has returned -13.66% so far this year and -27.60% over the past 12 months. Over the last ten years, AKBA has returned -17.31% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Mar 20, 2014, AKBA's average daily return is +0.06%, while the average monthly return is +1.08%. At this rate, your investment would double in approximately 5.4 years.

Historically, 46% of months were positive and 54% were negative. The best month was Dec 2022 with a return of +113.3%, while the worst month was Sep 2020 at -75.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.

On a daily basis, AKBA closed higher 47% of trading days. The best single day was Sep 9, 2015 with a return of +45.5%, while the worst single day was Sep 3, 2020 at -73.5%.

Akebia Therapeutics, Inc. has an annualized alpha of -2.19%, beta of 1.43, and R² of 0.09 versus S&P 500 Index. Calculated based on daily prices since March 21, 2014.

• This stock participated in 170.45% of S&P 500 Index downside but only 23.05% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.09 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

AKBA ranks 27 for risk / return — below 27% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Akebia Therapeutics, Inc. (AKBA) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Akebia Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Akebia Therapeutics, Inc. was 99.14%, occurring on Nov 29, 2022. The portfolio has not yet recovered.

The current Akebia Therapeutics, Inc. drawdown is 95.23%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Akebia Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Akebia Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.